Asset Details
Do you wish to reserve the book?
Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism
Do you wish to request the book?
Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism
2019
Overview
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by impaired social interactions, difficulty with communication, and repetitive behavior patterns. In humans affected by ASD, there is a male pre-disposition towards the condition with a male to female ratio of 4:1. In part due to the complex etiology of ASD including genetic and environmental interplay, there are currently no available medical therapies to improve the social deficits of ASD. Studies in rodent models and humans have shown promising therapeutic effects of oxytocin in modulating social adaptation. One pharmacological approach to stimulating oxytocinergic activity is the melanocortin receptor 4 agonist Melanotan-II (MT-II). Notably the effects of oxytocin on environmental rodent autism models has not been investigated to date. We used a maternal immune activation (MIA) mouse model of autism to assess the therapeutic potential of MT-II on autism-like features in adult male mice. The male MIA mice exhibited autism-like features including impaired social behavioral metrics, diminished vocal communication, and increased repetitive behaviors. Continuous administration of MT-II to male MIA mice over a seven-day course resulted in rescue of social behavioral metrics. Normal background C57 male mice treated with MT-II showed no significant alteration in social behavioral metrics. Additionally, there was no change in anxiety-like or repetitive behaviors following MT-II treatment of normal C57 mice, though there was significant weight loss following subacute treatment. These data demonstrate MT-II as an effective agent for improving autism-like behavioral deficits in the adult male MIA mouse model of autism.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ alpha-MSH - analogs & derivatives
/ Animals
/ Anxiety
/ Autism
/ Autistic Disorder - drug therapy
/ Behavior
/ Behavior, Animal - drug effects
/ Etiology
/ Female
/ Male
/ Medicine
/ Medicine and Health Sciences
/ Mice
/ Mutation
/ Neurodevelopmental disorders
/ Oxytocin
/ Peptides, Cyclic - therapeutic use
/ Pervasive developmental disorders
/ Receptor, Melanocortin, Type 4 - metabolism
/ Receptor, Melanocortin, Type 4 - physiology
/ Research and Analysis Methods
/ Rodents
